Rotigotine Objectively Improves Sleep in Parkinson’s Disease: An Open-Label Pilot Study with Actigraphic Recording
Table 2
Actigraphic and sleep diary results before (T0) and during (T1) rotigotine treatment.
T0
T1
Nocturnal actigraphic data
SL (min)
42 (15–65)
15 (8–40)
0.363
TST (min)
373 (321–424)
379 (298–399)
0.609
SE (%)
82 (64–87)
82 (71–88)
0.118
WASO (min)
122 (65–169)
83 (66–136)
0.069
N. of wake episodes
19 (11–21)
19 (16–26)
0.164
Mean duration of wake episodes (min)
9 (6–12)
7 (4–8)
0.002
ACmean (counts/min)
37 (26–51)
29 (24–41)
0.020
ACmedian (counts/min)
5 (0–27)
4 (0–16)
0.077
ACindex
53 (39–75)
54 (39–71)
0.349
Nocturnal sleep diary data
N. of good nights/week
3 (0–4)
4 (3–6)
0.004
N. of wake episodes
1 (0–2)
0 (0-1)
0.003
Total duration of wake episodes (min)
29 (5–60)
0 (0–38)
0.002
Diurnal actigraphic data
N. of sleep episodes
1 (1-2)
1 (1-1)
0.014
Total duration of sleep episodes (min)
70 (36–155)
57 (27–77)
0.011
Diurnal sleep diary data
N. of sleep episodes
1 (0-1)
0 (0-1)
0.046
Total duration of sleep episodes (min)
51 (17–94)
26 (9–69)
0.249
SL = sleep latency; min = minutes; TST = total sleep time; SE = sleep efficiency; WASO = wake after sleep onset; N. = number; ACmean = activity mean score; ACmedian = activity median score; ACindex = activity index. Data are expressed as median (25th–75th percentiles). = statistical significance .
